Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.

Literature DB >> 22962424

Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.

Verena Hartung-Knemeyer¹, Sandra Rosenbaum-Krumme, Christian Buchbender, Thorsten Pöppel, Wolfgang Brandau, Walter Jentzen, Gerald Antoch, Michael Forsting, Andreas Bockisch, Hilmar Kühl.

Abstract

Entities: Disease

Mesh：

Substances：
3-Iodobenzylguanidine

Year: 2012 PMID： 22962424 DOI： 10.1210/jc.2012-1958

Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Authors: Neeta Pandit-Taskar; Pat Zanzonico; Kevin D Staton; Jorge A Carrasquillo; Diane Reidy-Lagunes; Serge Lyashchenko; Eva Burnazi; Hanwen Zhang; Jason S Lewis; Ronald Blasberg; Steven M Larson; Wolfgang A Weber; Shakeel Modak
Journal: J Nucl Med Date: 2017-07-13 Impact factor: 10.057

2. Guidelines on nuclear medicine imaging in neuroblastoma.

Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236

Review 3. Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors: Rodney J Hicks; Michael S Hofman
Journal: Nat Rev Clin Oncol Date: 2012-11-13 Impact factor: 66.675

Review 4. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors: Victoria L Martucci; Karel Pacak
Journal: Curr Probl Cancer Date: 2014-01-15 Impact factor: 3.187

Review 5. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors: David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal: Endocr Relat Cancer Date: 2019-11 Impact factor: 5.678

6. Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results.

Authors: Karsten Beiderwellen; Michael Huebner; Philipp Heusch; Johannes Grueneisen; Verena Ruhlmann; Felix Nensa; Hilmar Kuehl; Lale Umutlu; Sandra Rosenbaum-Krumme; Thomas C Lauenstein
Journal: Eur Radiol Date: 2014-06-08 Impact factor: 5.315

7. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.

Authors: Elise M Blanchet; Corina Millo; Victoria Martucci; Roberto Maass-Moreno; David A Bluemke; Karel Pacak
Journal: Clin Nucl Med Date: 2014-03 Impact factor: 7.794

Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.

1. Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

2. Guidelines on nuclear medicine imaging in neuroblastoma.

Review 3. Is there still a role for SPECT-CT in oncology in the PET-CT era?

Review 4. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Review 5. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

6. Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results.

7. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.

Review 8. Norepinephrine Transporter as a Target for Imaging and Therapy.

9. The adrenal medulla and extra-adrenal paraganglia: then and now.

Review 10. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.

Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.

1. Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

2. Guidelines on nuclear medicine imaging in neuroblastoma.

Review 3. Is there still a role for SPECT-CT in oncology in the PET-CT era?

Review 4. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Review 5. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

6. Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results.

7. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.

Review 8. Norepinephrine Transporter as a Target for Imaging and Therapy.

9. The adrenal medulla and extra-adrenal paraganglia: then and now.

Review 10. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.

1. Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.